Matteo Santoni

14.4k total citations · 5 hit papers
357 papers, 8.8k citations indexed

About

Matteo Santoni is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Matteo Santoni has authored 357 papers receiving a total of 8.8k indexed citations (citations by other indexed papers that have themselves been cited), including 210 papers in Pulmonary and Respiratory Medicine, 173 papers in Oncology and 104 papers in Molecular Biology. Recurrent topics in Matteo Santoni's work include Renal cell carcinoma treatment (125 papers), Cancer Immunotherapy and Biomarkers (95 papers) and Cancer Genomics and Diagnostics (64 papers). Matteo Santoni is often cited by papers focused on Renal cell carcinoma treatment (125 papers), Cancer Immunotherapy and Biomarkers (95 papers) and Cancer Genomics and Diagnostics (64 papers). Matteo Santoni collaborates with scholars based in Italy, United States and Spain. Matteo Santoni's co-authors include Francesco Massari, Rodolfo Montironi, Giorgio Santoni, Massimo Nabissi, Maria Beatrice Morelli, Stefano Cascinu, Veronica Mollica, Liang Cheng, Consuelo Amantini and Marina Scarpelli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Matteo Santoni

340 papers receiving 8.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

2022 138 citations Matteo Rosellini, Andrea Marchetti et al. Nature Reviews Urology profile →
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study

2022 123 citations Matteo Santoni, Alessandro Rizzo et al. Critical Reviews in Oncology/Hematology profile →
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

2023 117 citations Matteo Santoni, Alessandro Rizzo et al. profile →
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study

2023 115 citations Veronica Mollica, Alessandro Rizzo et al. profile →
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study

2023 107 citations Alessandro Rizzo, Veronica Mollica et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matteo Santoni Italy	51	3.6k	3.3k	3.2k	2.0k	1.4k	357	8.8k
Yulin Liao China	56	1.9k 0.5×	2.0k 0.6×	5.8k 1.8×	2.8k 1.4×	1.5k 1.1×	244	11.5k
Thomas Fleming Germany	34	1.7k 0.5×	6.5k 2.0×	3.1k 1.0×	2.1k 1.0×	469 0.3×	110	11.9k
Stuart J. Shankland United States	70	1.5k 0.4×	1.3k 0.4×	6.8k 2.1×	752 0.4×	1.5k 1.1×	229	15.2k
Dalin He China	47	1.7k 0.5×	1.4k 0.4×	3.7k 1.1×	1.7k 0.8×	623 0.4×	275	6.5k
Sébastien Bonnet Canada	60	7.2k 2.0×	729 0.2×	5.0k 1.5×	2.6k 1.3×	1.3k 1.0×	192	11.6k
Li Li China	43	1.5k 0.4×	1.2k 0.4×	3.9k 1.2×	1.7k 0.8×	501 0.4×	262	6.3k
Gerald Höefler Austria	50	1.1k 0.3×	2.1k 0.6×	4.2k 1.3×	2.3k 1.1×	1.5k 1.1×	192	9.3k
Yasushi Shintani Japan	41	1.7k 0.5×	2.9k 0.9×	2.9k 0.9×	728 0.4×	1.4k 1.0×	310	8.1k
Takeshi Kubota Japan	37	1.7k 0.5×	1.2k 0.4×	1.4k 0.4×	848 0.4×	1.6k 1.2×	312	4.9k
Jason X.‐J. Yuan United States	60	5.9k 1.6×	364 0.1×	5.5k 1.7×	1.0k 0.5×	1.5k 1.0×	199	11.8k

Countries citing papers authored by Matteo Santoni

Since Specialization

Citations

This map shows the geographic impact of Matteo Santoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Santoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Santoni more than expected).

Fields of papers citing papers by Matteo Santoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Santoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Santoni. The network helps show where Matteo Santoni may publish in the future.

Co-authorship network of co-authors of Matteo Santoni

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Santoni. A scholar is included among the top collaborators of Matteo Santoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Santoni. Matteo Santoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Monteiro, Fernando Sabino Marques, Andrey Soares, Veronica Mollica, et al.. (2024). Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. 196. 104321–104321. 7 indexed citations

Roviello, Giandomenico, Matteo Santoni, Guru Sonpavde, & Martina Catalano. (2024). The evolving treatment landscape of metastatic urothelial cancer. Nature Reviews Urology. 21(10). 580–592. 11 indexed citations

Vitale, Elsa, Deniz Can Güven, Raffaella Massafra, et al.. (2024). Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis. Scientific Reports. 14(1). 28309–28309. 8 indexed citations

Antolini, E., Alessandra Filosa, Matteo Santoni, et al.. (2024). Internal Overview of Prostatic Cancer Cases and Quality of BRCA1 and BRCA2 NGS Data from the FFPE Tissue. Diagnostics. 14(18). 2067–2067.

Marchetti, Andrea, Matteo Rosellini, Elisa Tassinari, et al.. (2022). PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?. Cancers. 14(4). 907–907. 11 indexed citations

Mollica, Veronica, Andrea Marchetti, Matteo Rosellini, et al.. (2021). An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. International Journal of Molecular Sciences. 22(24). 13519–13519. 18 indexed citations

Mollica, Veronica, Alessandro Rizzo, Matteo Rosellini, et al.. (2021). Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. Cancers. 13(3). 546–546. 37 indexed citations

Aurilio, Gaetano, Matteo Santoni, Francesco Massari, et al.. (2021). Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. Cancers. 13(20). 5229–5229. 13 indexed citations

Morelli, Maria Beatrice, Consuelo Amantini, Marilena Gubbiotti, et al.. (2021). Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. Cancers. 13(23). 5989–5989. 12 indexed citations

10.

Cimadamore, Alessia, Roberta Mazzucchelli, Antonio López-Beltrán, et al.. (2021). Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation. Cancers. 13(14). 3471–3471. 8 indexed citations

11.

Incorvaia, Lorena, Lidia Rita Corsini, Chiara Brando, et al.. (2021). Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 163. 103390–103390. 5 indexed citations

12.

Santoni, Matteo, Francesco Piva, Camillo Porta, et al.. (2020). Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer. 19(2). e84–e91. 20 indexed citations

13.

Aurilio, Gaetano, Alessia Cimadamore, Matteo Santoni, et al.. (2020). New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. Cells. 9(6). 1522–1522. 8 indexed citations

14.

Piva, Francesco, Matteo Giulietti, Marco Maria Aiello, et al.. (2020). Predicting Future Cancer Burden in the United States By Artificial Neural Networks. Future Oncology. 17(2). 159–168. 9 indexed citations

15.

Montironi, Rodolfo, Alessia Cimadamore, Antonio López-Beltrán, et al.. (2020). Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. Cells. 9(5). 1073–1073. 36 indexed citations

16.

Bianconi, Maristella, Alessia Cimadamore, Luca Faloppi, et al.. (2019). Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. Therapeutic Advances in Urology. 11. 2077036940–2077036940. 7 indexed citations

17.

Santoni, Matteo, Daniel Yick Chin Heng, Gaetano Aurilio, et al.. (2019). Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Current Drug Targets. 21(4). 416–423. 5 indexed citations

18.

Aurilio, Gaetano, Francesco Piva, Matteo Santoni, et al.. (2019). The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. International Journal of Molecular Sciences. 20(22). 5683–5683. 36 indexed citations

19.

Grassi, Paolo, Ludovic Doucet, Viktor Grünwald, et al.. (2017). Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology. 92(5). 269–275. 3 indexed citations

20.

Bittoni, Alessandro, Kalliopi Andrikou, Andrea Lanese, et al.. (2015). Trattamento del carcinoma del pancreas. Attualità e prospettive. Recenti Progressi in Medicina. 106(5). 208–16. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact